No abstract available.
Colonic Pouches* ; Cystectomy* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

No abstract available.
Urinary Bladder Neoplasms* ; Urinary Bladder*

No abstract available.
Bacillus* ; Mitomycin* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

No abstract available.
Carcinoma, Renal Cell* ; Cell Line* ; Humans*

OBJECTIVE: To evaluate the effect of transduced tumor necrosis factor-a(TNF-a) gene expression on growth of human bladder tumor cell lines in vitro. MATERIALS AND METHODS: The complete cDNA of TNF-a was introduced to three human bladder tumor cell lines(F-24, J-82, HT-1197) using a retroviral vector, a recombinant form of Molony murine leukemia virus with TNF-a and Neo gene and transfected cells were selected by exposure to neomycin analog G418. Gene transfer and expression were confirmed by polymerase chain reaction(PCR) and reverse transcription polymerase chain reaction(RT-PCR)-Southern blotting. Cell growth was measured by MTT assay Result is Successful gene transfer and expression were confirmed in all three cell bladder tumor lines. Growth of transfected cells were compared with parental cell lines and no differences were found in all three cell lines(p>0.05). CONCLUSION: Expression of transduced TNF-t gene could not show any effect on growth of human bladder tumor cells in vitro.
Cell Line* ; DNA, Complementary ; Gene Expression* ; Genetic Therapy ; Humans* ; Leukemia Virus, Murine ; Necrosis ; Neomycin ; Parents ; Reverse Transcription ; Tumor Necrosis Factor-alpha* ; Urinary Bladder Neoplasms* ; Urinary Bladder* ; Zidovudine

No abstract available.
Urinary Tract*

No abstract available.
Carcinoma, Renal Cell* ; Prognosis*

We analyzed 57 patients with tuberculous nonfunctioning kidneys, which were diagnosed pathologically or bacteriologically at Seoul National University, from October 1981 to December 1989. The patients were divided into 3 groups according to the treatment ; Group 1 : 12 patients, only chemotherapy for more than 12 months ; Group 2 :32, nephrectomy and chemotherapy for more than 6 months ; Group 3 . 13, nephrectomy and chemotherapy only for 3 months. As a standard antituberculous regimen, isoniazid, rifampin, and ethambutol were used, and pyrazinamide was added in 15 patients. The follow-up tests were urinalysis, urine AFB smear and culture, and intravenous pyelography. The duration of the follow-up was 6 to 1O8 months, with a mean of 23.3 months. There was no evidence of recurrence in any patient among the 3 groups. Two postoperative complications (hematoma and fistula formation) occurred in 45 nephrectomized patients. Pathologic examination of the resected kidneys revealed findings compatible with tuberculosis in all patients of Groups 2 and 3. Coexisting cortical adenomas were found incidentally in 2 patients. Final diagnoses of the other 2 patients were hydronephrosis and chronic pyelonephritis without any evidence of tuberculosis, although these 2 patients were excluded in this study. Severe drug toxicity occurred in 7 patients that belonged to Groups 1 and 2. In conclusion, early nephrectomy for accurate diagnosis and removal of infective foci was the justifiable initial procedure, and this should be followed by postoperative antituberculous chemotherapy for the shortest acceptable period in tuberculous nonfunctioning kidneys. In highly selective cases where the lesion is completely localized in one kidney, we can consider early nephrectomy and a 3-month course of chemotherapy as one treatment modality.
Adenoma ; Diagnosis ; Drug Therapy ; Drug-Related Side Effects and Adverse Reactions ; Ethambutol ; Fistula ; Follow-Up Studies ; Humans ; Hydronephrosis ; Isoniazid ; Kidney* ; Nephrectomy ; Postoperative Complications ; Pyelonephritis ; Pyrazinamide ; Recurrence ; Rifampin ; Seoul ; Tuberculosis ; Urinalysis ; Urography

We analyzed the risk factors to the survival in 80 patients with advanced prostatic cancer who were managed in Seoul National University Hospital from 1979 to 1987. Variables were age, weight loss, hemoglobin, serum acid and alkaline phosphatase, pain, extent of metastasis on bone scan, Gleason`s sum metastatic site and treatment regimens. Univariate analysis using Logrank test and multivariate analysis of Cox`s proportional hazards regression model was performed. Median follow-up was 56 months (11-112) and median survival was 29 months in overall patients. The l, 3 and 5-year survival rate was 75%, 40%, and 17% respectively. In univariate analyses anemia, weight loss, Gleason`s sum, serum acid phosphatase, extent of metastasis on bone scan influenced the survival significantly(P<0.05). Multivariate analysis identified anemia and weight loss as the most important factor, followed by Gleason`s sum and the serum acid phosphatase level. serum acid phosphatase level. Based on these prognostic factors we divided the patients into 2 groups: the low and high risk group, with median survival of 44 and 15 months, 3 year survival rate of 64% and 4%, respectively. These prognostic factors and grouping may be useful for anticipating the fate of individual patient and the biologic behavior of the tumor. The effective management could be planned according to these criteria.
Acid Phosphatase ; Alkaline Phosphatase ; Anemia ; Follow-Up Studies ; Humans ; Multivariate Analysis ; Neoplasm Metastasis ; Prostatic Neoplasms* ; Risk Factors ; Seoul ; Survival Rate ; Weight Loss

Adenocarcinoma of the bladder is rare. During the last 20 years 13 patients with adenocarcinoma of the bladder were managed at Seoul National University Hospital. The incidence is 2.2% of all primary epithelial bladder neoplams. 10 patients had primary adenocarcinoma and urachal origins were identified in 3 patients. The most common presentation was painless gross hematuria. 9 of 10 patients with primary adenocarcinoma had deeply infiltrating tumor with or without distant metastasis at the time of initial diagnosis. Various interventions including TUR and partial cystectomy were carried out. In 5 patients postoperative radiation therapy was tried without substantial improvement. Three year survival rate of primary adenocarcinoma had was averaged less than 25% regardless of the mode of treatment. One patient was free of cancer up to 3 years. 3 patients with urachal adenocarcinoma had stage D of mucin producing adenocarcinoma. Partial cystectomy including enbloc excision of urachus in 1 was carried out, partial cystectomy in 1 and exploration for unresectable tumor in one patient who died in one year.
Adenocarcinoma* ; Cystectomy ; Diagnosis ; Hematuria ; Humans ; Incidence ; Mucins ; Neoplasm Metastasis ; Seoul ; Survival Rate ; Urachus ; Urinary Bladder Neoplasms ; Urinary Bladder*